The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
18
05
2018
accepted:
26
07
2019
revised:
15
07
2019
pubmed:
8
9
2019
medline:
15
5
2021
entrez:
8
9
2019
Statut:
ppublish
Résumé
The dopamine D2 and D3 receptors are implicated in schizophrenia and its pharmacological treatments. These receptors undergo intracellular trafficking processes that are modulated by dysbindin-1 (Dys). Indeed, Dys variants alter cognitive responses to antipsychotic drugs through D2-mediated mechanisms. However, the mechanism by which Dys might selectively interfere with the D3 receptor subtype is unknown. Here, we revealed an interaction between functional genetic variants altering Dys and D3. Specifically, both in patients with schizophrenia and in genetically modified mice, concomitant reduction in D3 and Dys functionality was associated with improved executive and working memory abilities. This D3/Dys interaction produced a D2/D3 imbalance favoring increased D2 signaling in the prefrontal cortex (PFC) but not in the striatum. No epistatic effects on the clinical positive and negative syndrome scale (PANSS) scores were evident, while only marginal effects on sensorimotor gating, locomotor functions, and social behavior were observed in mice. This genetic interaction between D3 and Dys suggests the D2/D3 imbalance in the PFC as a target for patient stratification and procognitive treatments in schizophrenia.
Identifiants
pubmed: 31492942
doi: 10.1038/s41380-019-0511-4
pii: 10.1038/s41380-019-0511-4
doi:
Substances chimiques
Dysbindin
0
Receptors, Dopamine D2
0
Receptors, Dopamine D3
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1272-1285Références
Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016;17:524–32.
pubmed: 27256556
pmcid: 5166560
Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A. Pathway-specific dopamine abnormalities in schizophrenia. Biol Psychiatry. 2017;81:31–42.
Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006;49:603–15.
pubmed: 16476668
Amato D, Vernon AC, Papaleo F. Dopamine, the antipsychotic molecule: a perspective on mechanisms underlying antipsychotic response variability. Neurosci Biobehav Rev. 2018;85:146–59.
pubmed: 28970021
Thompson D, Whistler JL. Dopamine D(3) receptors are down-regulated following heterologous endocytosis by a specific interaction with G protein-coupled receptor-associated sorting protein-1. J Biol Chem. 2011;286:1598–608.
pubmed: 21030592
Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladher F, Kharazia V, et al. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA. 2005;102:11521–6.
pubmed: 16049099
Manago F, Mereu M, Mastwal S, Mastrogiacomo R, Scheggia D, Emanuele M, et al. Genetic disruption of Arc/Arg3.1 in mice causes alterations in dopamine and neurobehavioral phenotypes related to schizophrenia. Cell Rep. 2016;16:2116–28.
pubmed: 27524619
pmcid: 5001893
Miyakawa T, Sumiyoshi S, Deshimaru M, Suzuki T, Tomonari H. Electron microscopic study on schizophrenia. Mechanism of pathological changes. Acta Neuropathol. 1972;20:67–77.
pubmed: 5020594
Schubert KO, Focking M, Prehn JH, Cotter DR. Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol psychiatry. 2012;17:669–81.
pubmed: 21986877
Canfran-Duque A, Barrio LC, Lerma M, de la Pena G, Serna J, Pastor O, et al. First-generation antipsychotic haloperidol alters the functionality of the late endosomal/lysosomal compartment in vitro. Int J Mol Sci. 2016;17:404.
pubmed: 26999125
pmcid: 4813259
Choi KH, Higgs BW, Weis S, Song J, Llenos IC, Dulay JR, et al. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC psychiatry. 2009;9:57.
pubmed: 19758435
pmcid: 2749837
Heusler P, Newman-Tancredi A, Loock T, Cussac D. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. Eur J Pharmacol. 2008;581:37–46.
pubmed: 18190908
Lester HA, Miwa JM, Srinivasan R. Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects. Biol psychiatry. 2012;72:907–15.
pubmed: 22771239
pmcid: 6167061
Tischbirek CH, Wenzel EM, Zheng F, Huth T, Amato D, Trapp S, et al. Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. Neuron. 2012;74:830–44.
pubmed: 22681688
Ji Y, Yang F, Papaleo F, Wang HX, Gao WJ, Weinberger DR, et al. Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proc Natl Acad Sci USA. 2009;106:19593–8.
pubmed: 19887632
Talbot K, Ong WY, Blake DJ, Tang J, Louneva N, Carlson GC et al. Dysbindin-1 and its protein family. In: Javitt DC, Kantrowitz J, editors. Handbook of Neurochemistry and Molecular Neurobiology, 3rd edn, vol. 27. Springer Science: New York; 2009, p 107–241.
Scheggia D, Mastrogiacomo R, Mereu M, Sannino S, Straub RE, Armando M, et al. Variations in dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nat Commun. 2018;9:2265.
pubmed: 29891954
pmcid: 5995960
Prats C, Arias B, Moya-Higueras J, Pomarol-Clotet E, Parellada M, Gonzalez-Pinto A, et al. Evidence of an epistatic effect between dysbindin-1 and neuritin-1 genes on the risk for schizophrenia spectrum disorders. Eur Psychiatry. 2017;40:60–64.
pubmed: 27855309
Papaleo F, Burdick MC, Callicott JH, Weinberger DR. Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. Mol Psychiatry. 2014;19:311–6.
pubmed: 24145376
Papaleo F, Weinberger DR. Dysbindin and schizophrenia: it’s dopamine and glutamate all over again. Biol psychiatry. 2011;69:2–4.
pubmed: 21145442
pmcid: 3021467
Papaleo F, Yang F, Garcia S, Chen J, Lu B, Crawley JN, et al. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol Psychiatry. 2012;17:85–98.
pubmed: 20956979
Sokoloff P, Le Foll B. The dopamine D3 receptor, a quarter century later. Eur J Neurosci. 2017;45:2–19.
pubmed: 27600596
Leggio GM, Bucolo C, Platania CB, Salomone S, Drago F. Current drug treatments targeting dopamine D3 receptor. Pharmacol Ther. 2016;165:164–77.
pubmed: 27343365
Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012;213:167–210.
Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, et al. The potential role of dopamine D(3) receptor neurotransmission in cognition. Eur Neuropsychopharmacol. 2013;23:799–813.
pubmed: 23791072
pmcid: 3748034
Clarkson RL, Liptak AT, Gee SM, Sohal VS, Bender KJ. D3 receptors regulate excitability in a unique class of prefrontal pyramidal cells. J Neurosci. 2017;37:5846–60.
pubmed: 28522735
pmcid: 5473204
Pich EM, Collo G. Pharmacological targeting of dopamine D3 receptors: possible clinical applications of selective drugs. Eur Neuropsychopharmacol. 2015;25:1437–47.
pubmed: 26298833
Maramai S, Gemma S, Brogi S, Campiani G, Butini S, Stark H, et al. Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases. Front Neurosci. 2016;10:451.
pubmed: 27761108
pmcid: 5050208
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15–31.
pubmed: 12908658
Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr. 2003;29:45–55.
Ceaser AE, Goldberg TE, Egan MF, McMahon RP, Weinberger DR, Gold JM. Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype? Biol psychiatry. 2008;64:782–8.
pubmed: 18597738
pmcid: 3466115
Eling P, Derckx K, Maes R. On the historical and conceptual background of the Wisconsin Card Sorting Test. Brain Cognit. 2008;67:247–53.
Scheggia D, Bebensee A, Weinberger DR, Papaleo F. The ultimate intra-/extra-dimensional attentional set-shifting task for mice. Biol psychiatry. 2014;75:660–70.
pubmed: 23810621
Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA. 1996;93:1945–9.
pubmed: 8700864
Papaleo F, Lipska BK, Weinberger DR. Mouse models of genetic effects on cognition: relevance to schizophrenia. Neuropharmacology. 2012;62:1204–20.
pubmed: 21557953
Mereu M, Contarini G, Buonaguro EF, Latte G, Manago F, Iasevoli F, et al. Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder. Neuropharmacology. 2017;121:179–94.
pubmed: 28454982
Torrisi SA, Salomone S, Geraci F, Caraci F, Bucolo C, Drago F, et al. Buspirone counteracts MK-801-induced schizophrenia-like phenotypes through dopamine D3 receptor blockade. Front Pharmacol. 2017;8:710.
pubmed: 29046641
pmcid: 5632784
Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, Weinberger DR, et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci. 2008;28:8709–23.
pubmed: 18753372
pmcid: 2561993
Huang H, Michetti C, Busnelli M, Manago F, Sannino S, Scheggia D, et al. Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacology. 2014;39:1102–14.
pubmed: 24190025
Scheggia D, Zamberletti E, Realini N, Mereu M, Contarini G, Ferretti V et al. Remote memories are enhanced by COMT activity through dysregulation of the endocannabinoid system in the prefrontal cortex. Mol Psychiatry. 2018;23:1040–50.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.
pubmed: 16172203
Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci USA. 2006;103:10753–8.
pubmed: 16809426
Papaleo F, Sannino S, Piras F, Spalletta G. Sex-dichotomous effects of functional COMT genetic variations on cognitive functions disappear after menopause in both health and schizophrenia. Eur Neuropsychopharmacol. 2015;25:2349–63.
pubmed: 26560201
Sannino S, Gozzi A, Cerasa A, Piras F, Scheggia D, Manago F, et al. COMT genetic reduction produces sexually divergent effects on cortical anatomy and working memory in mice and humans. Cereb Cortex. 2015;25:2529–41.
pubmed: 24658585
Lidow MS, Wang F, Cao Y, Goldman-Rakic PS. Layer V neurons bear the majority of mRNAs encoding the five distinct dopamine receptor subtypes in the primate prefrontal cortex. Synapse. 1998;28:10–20.
pubmed: 9414013
Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14:1–21.
pubmed: 11253953
Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci. 2007;10:376–84.
pubmed: 17277774
Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov today. 2005;10:917–25.
pubmed: 15993811
Hida H, Mouri A, Mori K, Matsumoto Y, Seki T, Taniguchi M, et al. Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D(3)-5-HT(2)A and D(1)-NMDA receptors in the mPFC. Neuropsychopharmacology. 2015;40:601–13.
pubmed: 25120077
Swerdlow NR. Update: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome. Neurosci Biobehav Rev. 2013;37:1150–6.
pubmed: 23017868
Mohr D, Pilz PK, Plappert CF, Fendt M. Accumbal dopamine D2 receptors are important for sensorimotor gating in C3H mice. Neuroreport. 2007;18:1493–7.
pubmed: 17712281
Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology. 2001;156:234–58.
pubmed: 11549226
Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen psychiatry. 2006;63:1325–35.
pubmed: 17146007
Paylor R, Glaser B, Mupo A, Ataliotis P, Spencer C, Sobotka A, et al. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc Natl Acad Sci USA. 2006;103:7729–34.
pubmed: 16684884
van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr. 2010;36:246–70.
Halberstadt AL, Geyer MA. Habituation and sensitization of acoustic startle: opposite influences of dopamine D1 and D2-family receptors. Neurobiol Learn Mem. 2009;92:243–8.
pubmed: 18644244
Plappert CF, Pilz PK, Schnitzler HU. Factors governing prepulse inhibition and prepulse facilitation of the acoustic startle response in mice. Behav brain Res. 2004;152:403–12.
pubmed: 15196809
Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004;27:683–90.
pubmed: 15474169
Glickstein SB, Desteno DA, Hof PR, Schmauss C. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb cortex. 2005;15:1016–24.
pubmed: 15537671
Schmieg N, Rocchi C, Romeo S, Maggio R, Millan MJ, Mannoury la Cour C. Dysbindin-1 modifies signaling and cellular localization of recombinant, human D(3) and D(2) receptors. J Neurochem. 2016;136:1037–51.
pubmed: 26685100
Dembrow NC, Chitwood RA, Johnston D. Projection-specific neuromodulation of medial prefrontal cortex neurons. J Neurosci. 2010;30:16922–37.
pubmed: 21159963
pmcid: 3075873
Gee S, Ellwood I, Patel T, Luongo F, Deisseroth K, Sohal VS. Synaptic activity unmasks dopamine D2 receptor modulation of a specific class of layer V pyramidal neurons in prefrontal cortex. J Neurosci. 2012;32:4959–71.
pubmed: 22492051
pmcid: 3352768
Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry. 1997;54:225–32.
pubmed: 9075463
Cui Y, Prabhu V, Nguyen TB, Yadav BK, Chung YC. The mRNA expression status of dopamine receptor D2, dopamine receptor D3 and DARPP-32 in T lymphocytes of patients with early psychosis. Int J Mol Sci. 2015;16:26677–86.
pubmed: 26561806
pmcid: 4661842